Dec 19, 2024
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Read more
Dec 19, 2024
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Read more
Nov 09, 2024
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Read more
Oct 29, 2024
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
Read more
Oct 07, 2024
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Read more
Displaying 1 - 10 of 50